All engineered peptides articles
-
NewsCARB-X funds Peptilogics to develop a novel, broad-spectrum therapeutic to treat fracture-related infections
CARB-X will award Peptilogics US$3.3 million to develop and execute a workplan for its slow-release formulation of a novel, broad-spectrum therapeutic, zaloganan-CR, an engineered peptide intended for use in preventing infection after high-energy-traumatic bone injuries.
